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Vitamin C deficiency, or scurvy, is uncommon in
the Western world. Here, we present a patient who
had scurvy diagnosed while receiving vemurafenib
treatment for metastatic melanoma, which improved
with vitamin C supplementation.CASE REPORT
A66-year-oldwhitemanwith stage IIICmelanoma
diagnosed in 2009 was treated with high-dose inter-
feron alfa-2b for 1 year. He subsequently had subcu-
taneous and brainmetastases and underwent 2 cycles
of high-dose interleukin-2 and whole-brain irradia-
tion. Given disease progression, vemurafenib was
initiated at 960 mg twice daily after testing confirmed
the BRAF V600E mutation. After 4 months of treat-
ment, systemic symptoms of severe fatigue,
anorexia/dysgeusia, and arthralgias developed as
did cutaneous manifestations including xerosis, a
keratosis pilariselike eruption on the trunk and
extremities, and corkscrew hairs on the upper back,
which were not present before vemurafenib therapy
(Figs 1 and 2). The clinical symptomswere consistent
with several reported side effects of vemurafenib;
however, the additional finding of corkscrew hairs
prompted the consideration of vitamin C deficiency
resulting in scurvy. Other findings of scurvy such as
petechiae, gingivitis, and poor wound healing were
not present. Further investigation found low plasma
vitamin C levels on 2 independent determinations 1
week apart (0.0 mg/dL and 0.1 mg/dL [0.4e2.0 mg/
dL]). Upon questioning, the patient reported
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Therapeutic supplementation of ascorbic acid (125
mg twice daily) and increased dietary consumption
of foods rich in vitamin Cwere recommended; after 6
weeks, a vitamin C level was within normal limits at
0.7mg/d, and he experienced significant reduction in
fatigue and arthralgias. After 12 weeks, the keratosis
pilariselike eruption improved, and the corkscrew
hairs resolved (Fig 3). Thepatient’s vemurafenib dose
remained stable throughout this time. Within 1
month, the patient had recurrence in the right axilla
and brain; he died from his disease 8months after the
diagnosis of scurvy.DISCUSSION
Cutaneous side effects associated with vemurafe-
nib include photosensitivity, alopecia, xerosis, pap-
illomas, squamous cell carcinomas, panniculitis,
keratosis pilariselike eruptions, facial erythema,
palmar-plantar hyperkeratosis, and acneiform erup-
tions.1-4 Dysgeusia and decreased appetite are com-
mon side effects, reported in 13% and 18.8%,
respectively, of 468 patients combined from the
phase II and phase III trials.5 It is not known if
vemurafenib directly contributes to vitamin C defi-
ciency or if the association is mediated by the
symptoms of anorexia and taste disturbance, which
may lead to decreased consumption of fruits and
vegetables. After this patient had vitamin C defi-
ciency diagnosed, we measured vitamin C levels in 3
other patients taking vemurafenib. We identified 1
patient with vitamin C deficiency who did not have
any signs or symptoms of scurvy (particularly noOne patient described in this manuscript was presented in a
poster accepted for presentation at the Society for Melanoma
Research meeting in Philadelphia, PA on November 17, 2013.
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Fig 3. Resolution of corkscrew hairs and improvement in
keratosis pilariselike eruptionafter treatmentwith vitaminC.
Fig 1. Clinical presentation of scurvy. Perifollicular ery-
thema, keratosis pilariselike eruption, and corkscrew
hairs on the upper back of a patient with vitamin C
deficiency receiving vemurafenib for metastatic melanoma
(inset with higher magnification of corkscrew hair sur-
rounded by ink dots).
Fig 2. Histopathologic presentation of scurvy. Punch
biopsy of a corkscrew hair shows a hair shaft cut on
multiple cross sections with a rare eosinophil underlying
the dermis. (Hematoxylin-eosin stain, original magnifica-
tions 34 and inset, 320.)
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the keratosis pilariselike eruption (no corkscrew
hairs) had normal vitamin C levels. Therefore, we
cannot conclude whether there is a direct relation-
ship between vemurafenib and vitamin C deficiency
or whether the association is mediated simply by
decreased appetite or metastatic disease. Currently,
we obtain baseline vitamin C levels on patients
before treatment with vemurafenib and follow-up
levels if symptoms of scurvy or decreased appetite
are present. Given that scurvy rarely occurs in the
United States, it is important for dermatologists and
oncologists to be aware of this potential association
so that they can monitor patients for symptoms and
test and treat accordingly.
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